TICKERNERD
Menu
KALAKALAHealthcare · Biotechnology

KALA Stock Forecast: Kala Bio, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$0.30
−17.61% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 8 Oct 2026 — in the weakest quartile.

Market cap
$7.0M
Ticker Nerd rank
17 / 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$1.7M
Net income−$1.6M
Free cash flow−$1.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−29.2%
1M
−44.9%
YTD
−98.9%
1Y
−99.6%
From 52W high
−99.6%
From 52W low
0.0%
$0
$79
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KALA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kala Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
17 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
95
Growth
70
Issuance
55
Accruals
42
Revisions
25
Volatility
17
Quality
12
Value
1
Momentum
1

Size (95): Smaller than most of the companies we track.

Momentum (1): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KALA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KALA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Jan 26Apr 26Jul 26Oct 26KALA

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 Sept 2025HC Wainwright & Co.DowngradeNeutral—
17 Sept 2025HC Wainwright & Co.MaintainsBuy—
11 Sept 2025OppenheimerMaintainsOutperform—
8 Sept 2025MizuhoInitiatesOutperform—
11 July 2025Ladenburg ThalmannInitiatesBuy—
2 June 2025OppenheimerAssumesOutperform$15
23 May 2025HC Wainwright & Co.MaintainsBuy—
4 Apr 2025HC Wainwright & Co.ReiteratesBuy—
13 Feb 2025HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
19 Aug 2024OppenheimerReiteratesOutperform—
17 May 2024HC Wainwright & Co.MaintainsBuy—
2 Apr 2024HC Wainwright & Co.MaintainsBuy—
1 Apr 2024OppenheimerReiteratesOutperform—
17 Nov 2023HC Wainwright & Co.MaintainsBuy—
11 Aug 2023HC Wainwright & Co.ReiteratesBuy—
10 May 2023HC Wainwright & Co.ReiteratesBuy—
1 May 2023HC Wainwright & Co.ReiteratesBuy—
12 Apr 2023HC Wainwright & Co.MaintainsBuy—
27 Mar 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KALA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KALA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Kala Bio, Inc. returned −99.6% against +16.2% for the S&P 500, dividends included.

KALA vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26KALAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KALA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Kala Bio, Inc. (KALA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
11.4×

Cheaper than 54% of US stocks

Price / sales
—
Price / book
0.7×

Cheaper than 81% of US stocks

EV / EBITDA
0.0×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−345.3%

Higher than 4% of US stocks

Return on assets
−65.4%

Higher than 5% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kala Bio, Inc. (KALA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kala Bio, Inc. has a market value of $7.0M and an enterprise value of −$189K.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$10.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$19.9M.

  • Shares outstanding: 19.3M.

  • Trailing P/E: 11.4×; forward P/E: −0.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Kala Bio, Inc. employs 6 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

KALA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KALAKala Bio, Inc.$7.0M
17
CDIOCardio Diagnostics Holdings, Inc.$5.5M
21
PULMPulmatrix, Inc.$5.6M
47
CELZCreative Medical Technology Holdings, Inc.$5.7M
18
LNAILunai Bioworks, Inc.$5.1M
34
IMNNImunon, Inc.$6.0M
24
LIMNLiminatus Pharma, Inc.$5.0M
15

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kala Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KALA news & analysis

KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception

Newsfile Corp · 29 Sept 2026positive

KALA Bio announced on September 24, 2026 that it signed a non-binding letter of intent to acquire 100% of a privately held U.S.-based telehealth platform for approximately $15 million, payable in cash and stock. The target, a LegitScript-certified, NABP-accredited platform serving clients in all 50 states with over 90,000 clients, generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 and is cash-flow positive. The due diligence period is expected to conclude in November 2026, with closing targeted for late 2026 or early 2027.

Why it matters — The proposed acquisition would expand KALA's reach into a 50-state telehealth platform focused on peptides such as GLP-1 weight management, hormone health, longevity, and sexual wellness.

Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products

GlobeNewsWire · 24 Sept 2026positive

Kala Bio and Virotek signed a letter of intent with a U.S. DNA testing platform to resell Virotek's suite of genetic testing products. The agreement would expand their genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel.

Why it matters — KALA watchers would care because the agreement signals an expansion of Kala Bio's genetic testing collaboration into new product areas and an additional U.S. distribution channel beyond ophthalmology.

KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team

GlobeNewsWire · 17 Sept 2026positive

KALA Bio announced that healthcare operator Yenvy Truong, founder of The LSM Group, has joined its advisory team. Truong will support KALA's growth across its existing business and potential acquisitions.

Why it matters — KALA watchers may see the addition of an experienced healthcare operator to its advisory team as a signal of support for the company's expansion and acquisition strategy.

Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

GlobeNewsWire · 3 Sept 2026positive

Kala Bio and Virotek have finalized a definitive agreement under which Kala receives exclusive U.S. rights to market and distribute Virotek's ophthalmology genomic testing program. The partnership grants Kala sole U.S. distribution rights for the program.

Why it matters — This expands Kala's ophthalmology offerings beyond its existing pipeline into genetic testing, giving it a new exclusive commercial foothold in the U.S. market.

Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

GlobeNewsWire · 1 Sept 2026positive

Kala Bio and Virotek announced a letter of intent to negotiate a definitive agreement under which Kala would become the exclusive U.S. distributor and reseller of Virotek's genetic testing and screening program for ophthalmological indications. Virotek is a CLIA-registered precision health and clinical genomics company.

Why it matters — The LOI outlines a potential new U.S. distribution partnership that could add an ophthalmology genetic testing program to Kala's offerings.

FAQ

Frequently asked questions about KALA stock

Is KALA stock a buy right now?

Of the 1 analysts covering Kala Bio, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kala Bio, Inc. 17 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KALA?

As at 8 Oct 2026, Kala Bio, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

What is the KALA stock forecast for 2030?

No analyst covering Kala Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KALA are extrapolating price history, which says nothing about the business.

How has KALA stock performed over the past year?

Kala Bio, Inc. returned -99.6% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kala Bio, Inc. do?

KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and severe diseases of the eye.

What is the latest news on KALA?

The most recent item we track (Newsfile Corp, 29 Sept 2026): "KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception". KALA Bio announced on September 24, 2026 that it signed a non-binding letter of intent to acquire 100% of a privately held U.S.-based telehealth platform for approximately $15 million, payable in cash and stock. The target, a LegitScript-certified, NABP-accredited platform serving clients in all 50 states with over 90,000 clients, generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 and is cash-flow positive. The due diligence period is expected to conclude in November 2026, with closing targeted for late 2026 or early 2027.

Company

About Kala Bio, Inc.

KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and severe diseases of the eye. KALA BIO’s current work centers on biologics-based investigational treatments built on its proprietary mesenchymal stem cell secretome platform, with KPI-012 as its lead product candidate for persistent corneal epithelial defects and other corneal disorders. The company also evaluates the platform for broader ophthalmic applications, including limbal stem cell deficiency and retinal degenerative diseases. KALA BIO serves the biotechnology and pharmaceutical research space through its development pipeline and commercialization efforts, with an emphasis on unmet medical needs in eye health. Headquartered in Arlington, Massachusetts, KALA BIO operates as a specialized participant in the ophthalmology and biotechnology markets.

CEO Mr. Avi Minkowitz · 6 employees · United States · https://www.kalarx.com